323 related articles for article (PubMed ID: 31759166)
21. JAK-STAT signaling regulation of chicken embryonic stem cell differentiation into male germ cells.
Zhang Y; Zhang L; Zuo Q; Wang Y; Zhang Y; Xu Q; Li B; Chen G
In Vitro Cell Dev Biol Anim; 2017 Sep; 53(8):728-743. PubMed ID: 28597334
[TBL] [Abstract][Full Text] [Related]
22. Developmental expression of chicken FOXN1 and putative target genes during feather development.
Darnell DK; Zhang LS; Hannenhalli S; Yaklichkin SY
Int J Dev Biol; 2014; 58(1):57-64. PubMed ID: 24860996
[TBL] [Abstract][Full Text] [Related]
23. Constitutive JAK/STAT signaling is the primary mechanism of resistance to JAKi in TYK2-rearranged acute lymphoblastic leukemia.
Tavakoli Shirazi P; Eadie LN; Page EC; Heatley SL; Bruning JB; White DL
Cancer Lett; 2021 Aug; 512():28-37. PubMed ID: 33971281
[TBL] [Abstract][Full Text] [Related]
24. IL-4 and IL-13 employ discrete signaling pathways for target gene expression in alternatively activated monocytes/macrophages.
Bhattacharjee A; Shukla M; Yakubenko VP; Mulya A; Kundu S; Cathcart MK
Free Radic Biol Med; 2013 Jan; 54():1-16. PubMed ID: 23124025
[TBL] [Abstract][Full Text] [Related]
25. The growth hormone receptor associates with Jak1, Jak2 and Tyk2 in human liver.
Hellgren G; Jansson JO; Carlsson LM; Carlsson B
Growth Horm IGF Res; 1999 Jun; 9(3):212-8. PubMed ID: 10502458
[TBL] [Abstract][Full Text] [Related]
26. Luteolin sensitizes the antiproliferative effect of interferon α/β by activation of Janus kinase/signal transducer and activator of transcription pathway signaling through protein kinase A-mediated inhibition of protein tyrosine phosphatase SHP-2 in cancer cells.
Tai Z; Lin Y; He Y; Huang J; Guo J; Yang L; Zhang G; Wang F
Cell Signal; 2014 Mar; 26(3):619-28. PubMed ID: 24333668
[TBL] [Abstract][Full Text] [Related]
27. Activation of the protein tyrosine phosphatase SHP2 via the interleukin-6 signal transducing receptor protein gp130 requires tyrosine kinase Jak1 and limits acute-phase protein expression.
Schaper F; Gendo C; Eck M; Schmitz J; Grimm C; Anhuf D; Kerr IM; Heinrich PC
Biochem J; 1998 Nov; 335 ( Pt 3)(Pt 3):557-65. PubMed ID: 9794795
[TBL] [Abstract][Full Text] [Related]
28. Expression of genes belonging to the interacting TLR cascades, NADPH-oxidase and mitochondrial oxidative phosphorylation in septic patients.
Nucci LA; Santos SS; Brunialti MK; Sharma NK; Machado FR; Assunção M; de Azevedo LC; Salomao R
PLoS One; 2017; 12(2):e0172024. PubMed ID: 28182798
[TBL] [Abstract][Full Text] [Related]
29. Janus kinase 2--a novel negative regulator of estrogen receptor α function.
Gupta N; Grebhardt S; Mayer D
Cell Signal; 2012 Jan; 24(1):151-61. PubMed ID: 21907792
[TBL] [Abstract][Full Text] [Related]
30. Role of angiotensin II in activation of the JAK/STAT pathway induced by acute pressure overload in the rat heart.
Pan J; Fukuda K; Kodama H; Makino S; Takahashi T; Sano M; Hori S; Ogawa S
Circ Res; 1997 Oct; 81(4):611-7. PubMed ID: 9314843
[TBL] [Abstract][Full Text] [Related]
31. Gene and protein expression profiles of JAK-STAT signalling pathway in the developing brain of the Ts1Cje down syndrome mouse model.
Lee HC; Md Yusof HH; Leong MP; Zainal Abidin S; Seth EA; Hewitt CA; Vidyadaran S; Nordin N; Scott HS; Cheah PS; Ling KH
Int J Neurosci; 2019 Sep; 129(9):871-881. PubMed ID: 30775947
[No Abstract] [Full Text] [Related]
32. Acute lymphoblastic leukemia-associated JAK1 mutants activate the Janus kinase/STAT pathway via interleukin-9 receptor alpha homodimers.
Hornakova T; Staerk J; Royer Y; Flex E; Tartaglia M; Constantinescu SN; Knoops L; Renauld JC
J Biol Chem; 2009 Mar; 284(11):6773-81. PubMed ID: 19139102
[TBL] [Abstract][Full Text] [Related]
33. JAK1 and Tyk2 activation by the homologous polycythemia vera JAK2 V617F mutation: cross-talk with IGF1 receptor.
Staerk J; Kallin A; Demoulin JB; Vainchenker W; Constantinescu SN
J Biol Chem; 2005 Dec; 280(51):41893-9. PubMed ID: 16239216
[TBL] [Abstract][Full Text] [Related]
34. Respirovirus C protein inhibits activation of type I interferon receptor-associated kinases to block JAK-STAT signaling.
Kitagawa Y; Yamaguchi M; Kohno M; Sakai M; Itoh M; Gotoh B
FEBS Lett; 2020 Mar; 594(5):864-877. PubMed ID: 31705658
[TBL] [Abstract][Full Text] [Related]
35. Selective JAK1 inhibitor and selective Tyk2 inhibitor patents.
Norman P
Expert Opin Ther Pat; 2012 Oct; 22(10):1233-49. PubMed ID: 22971156
[TBL] [Abstract][Full Text] [Related]
36. Structural and Functional Characterization of the JH2 Pseudokinase Domain of JAK Family Tyrosine Kinase 2 (TYK2).
Min X; Ungureanu D; Maxwell S; Hammarén H; Thibault S; Hillert EK; Ayres M; Greenfield B; Eksterowicz J; Gabel C; Walker N; Silvennoinen O; Wang Z
J Biol Chem; 2015 Nov; 290(45):27261-27270. PubMed ID: 26359499
[TBL] [Abstract][Full Text] [Related]
37. JAK3 as an Emerging Target for Topical Treatment of Inflammatory Skin Diseases.
Alves de Medeiros AK; Speeckaert R; Desmet E; Van Gele M; De Schepper S; Lambert J
PLoS One; 2016; 11(10):e0164080. PubMed ID: 27711196
[TBL] [Abstract][Full Text] [Related]
38. The antagonist of the JAK-1/STAT-1 signaling pathway improves the severity of cerulein-stimulated pancreatic injury via inhibition of NF-κB activity.
Chen P; Huang L; Zhang Y; Qiao M; Yao W; Yuan Y
Int J Mol Med; 2011 May; 27(5):731-8. PubMed ID: 21369693
[TBL] [Abstract][Full Text] [Related]
39. English version of Japanese guidance for the use of oral Janus kinase inhibitors (JAK1 and TYK2 inhibitors) in the treatments of psoriasis.
Saeki H; Mabuchi T; Asahina A; Abe M; Igarashi A; Imafuku S; Okubo Y; Komine M; Takahashi K; Torii H; Morita A; Yotsuyanagi H; Watanabe A; Ohtsuki M;
J Dermatol; 2023 May; 50(5):e138-e150. PubMed ID: 37132187
[TBL] [Abstract][Full Text] [Related]
40. Deucravacitinib is an allosteric TYK2 protein kinase inhibitor FDA-approved for the treatment of psoriasis.
Roskoski R
Pharmacol Res; 2023 Mar; 189():106642. PubMed ID: 36754102
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
